The DOI matches its Crossref record; 136 of the 136 references it cites were found in a registry or an index.
Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review)
Open accessAbstract
Cisplatin is one of the most effective chemotherapy drugs for ovarian cancer, but resistance is common. The initial response to platinum‑based chemotherapy is as high as 80%, but in most advanced patients, final relapse and death are caused by acquired drug resistance. The development of resistance to therapy in ovarian cancer is a significant hindrance to therapeutic efficacy. The resistance of ovarian cancer cells to chemotherapeutic mechanisms is rather complex and includes multidrug resistance, DNA damage repair, cell metabolism, oxidative stress, cell cycle regulation, cancer stem cells, immunity, apoptotic pathways, autophagy and abnormal signaling pathways. The present review provided an update of recent developments in our understanding of the mechanisms of ovarian cancer platinum‑based chemotherapy resistance, discussed current and emerging approaches for targeting these patients and presented challenges associated with these approaches, with a focus on development and overcoming resistance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Janzen, D. M., Tiourin, E., Salehi, J. A., Paik, D. Y., Lu, J. N., Pellegrini, M. A., & Memarzadeh, S. (2015) · Nature Communications · doi:10.1038/ncomms8956 · Cited by 72
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
Identification and Characterization of Ovarian Cancer-Initiating Cells from Primary Human Tumors
Zhang, S., Balch, C., Chan, M. W., Lai, H.-C., Matei, D., Schilder, J. M., Yan, P. S., Huang, T. H.-M., & Nephew, K. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0364 · Cited by 1,293
A transforming mutation in the pleckstrin homology domain of AKT1 in cancer
Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M., Hostetter, G., Boguslawski, S., Moses, T. Y., Savage, S., et al. (2007) · Nature · doi:10.1038/nature05933 · Cited by 1,292
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Alsop, K., Fereday, S., Meldrum, C., deFazio, A., Emmanuel, C., George, J., Dobrovic, A., Birrer, M. J., Webb, P. M., Stewart, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.8545 · Cited by 1,180
Targeting metabolic transformation for cancer therapy
Tennant, D. A., Durán, R. V., & Gottlieb, E. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2817 · Cited by 1,059
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity
Chandarlapaty, S., Sawai, A., Scaltriti, M., Rodrik-Outmezguine, V., Grbovic-Huezo, O., Serra, V., Majumder, P. K., Baselga, J., & Rosen, N. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.10.031 · Cited by 967
Unravelling cancer stem cell potential
Beck, B., & Blanpain, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3597 · Cited by 905
Itoh, K., Tong, K. I., & Yamamoto, M. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.075 · Cited by 864
Role of Macrophage Targeting in the Antitumor Activity of Trabectedin
Germano, G., Frapolli, R., Belgiovine, C., Anselmo, A., Pesce, S., Liguori, M., Erba, E., Uboldi, S., Zucchetti, M., Pasqualini, F., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.01.008 · Cited by 864
Chen, A. M., Zhang, M., Wei, D., Stueber, D., Taratula, O., Minko, T., & He, H. (2009) · Small · doi:10.1002/smll.200900621 · Cited by 671
Telomeric Allelic Imbalance Indicates Defective DNA Repair and Sensitivity to DNA-Damaging Agents
Birkbak, N. J., Wang, Z. C., Kim, J.-Y., Eklund, A. C., Li, Q., Tian, R., Bowman-Colin, C., Li, Y., Greene-Colozzi, A., Iglehart, J. D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0206 · Cited by 661
Self-citationHow the Warburg effect supports aggressiveness and drug resistance of cancer cells?
Icard, P., Shulman, S., Farhat, D., Steyaert, J.-M., Alifano, M., & Lincet, H. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.001 · Cited by 643
Targeting DNA Repair in Cancer: Beyond PARP Inhibitors
Brown, J. S., O'Carrigan, B., Jackson, S. P., & Yap, T. A. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0860 · Cited by 618
Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy
Chonghaile, T. N., Sarosiek, K. A., Vo, T.-T., Ryan, J. A., Tammareddi, A., Moore, V. D. G., Deng, J., Anderson, K. C., Richardson, P., Tai, Y.-T., et al. (2011) · Science · doi:10.1126/science.1206727 · Cited by 585
Norquist, B., Wurz, K. A., Pennil, C. C., Garcia, R., Gross, J., Sakai, W., Karlan, B. Y., Taniguchi, T., & Swisher, E. M. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.2980 · Cited by 577
Autophagy in health and disease: A comprehensive review
Saha, S., Panigrahi, D. P., Patil, S., & Bhutia, S. K. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.007 · Cited by 517
Roles of p53, MYC and HIF-1 in regulating glycolysis–the seventh hallmark of cancer
Yeung, S. J., Pan, J., & Lee, M.-H. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8224-x · Cited by 514
Silva, I. A., Bai, S., McLean, K., Yang, K., Griffith, K., Thomas, D., Ginestier, C., Johnston, C., Kueck, A., Reynolds, R. K., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3175 · Cited by 514
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance
Aksamitiene, E., Kiyatkin, A., & Kholodenko, B. N. (2012) · Biochemical Society Transactions · doi:10.1042/bst20110609 · Cited by 479
Gewinner, C., Wang, Z. C., Richardson, A., Teruya-Feldstein, J., Etemadmoghadam, D., Bowtell, D., Barretina, J., Lin, W. M., Rameh, L., Salmena, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.06.006 · Cited by 461
Guan, B., Wang, T.-L., & Shih, I.-M. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1562 · Cited by 442
Disis, M. L., Taylor, M. H., Kelly, K., Beck, J. T., Gordon, M., Moore, K. M., Patel, M. R., Chaves, J., Park, H., Mita, A. C., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.6258 · Cited by 437
Lin, K. K., Harrell, M. I., Oza, A. M., Oaknin, A., Ray-Coquard, I., Tinker, A. V., Helman, E., Radke, M. R., Say, C., Vo, L.-T., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0715 · Cited by 432
Kleih, M., Böpple, K., Dong, M., Gaißler, A., Heine, S., Olayioye, M. A., Aulitzky, W. E., & Essmann, F. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-2081-4 · Cited by 422
Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells
Baba, T., Convery, P. A., Matsumura, N., Whitaker, R. S., Kondoh, E., Perry, T., Huang, Z., Bentley, R. C., Mori, S., Fujii, S., et al. (2009) · Oncogene · doi:10.1038/onc.2008.374 · Cited by 419
Kondrashova, O., Nguyen, M., Shield-Artin, K., Tinker, A. V., Teng, N. N. H., Harrell, M. I., Kuiper, M. J., Ho, G.-Y., Barker, H., Jasin, M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0419 · Cited by 407
Kim, H., Xu, H., George, E., Hallberg, D., Kumar, S., Jagannathan, V., Medvedev, S., Kinose, Y., Devins, K., Verma, P., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17127-2 · Cited by 362
Constantinidou, A., Alifieris, C., & Trafalis, D. T. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.09.008 · Cited by 342
Diagnosis and Treatment of Ovarian Cancer
Orr, B., & Edwards, R. P. (2018) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2018.07.010 · Cited by 322
Cisplatin induced Mitochondrial DNA damage in dorsal root ganglion neurons
Podratz, J. L., Knight, A. M., Ta, L. E., Staff, N. P., Gass, J. M., Genelin, K., Schlattau, A., Lathroum, L., & Windebank, A. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.11.017 · Cited by 320
Epigenetic therapy for ovarian cancer: promise and progress
Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 319
PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers
Gentric, G., Kieffer, Y., Mieulet, V., Goundiam, O., Bonneau, C., Nemati, F., Hurbain, I., Raposo, G., Popova, T., Stern, M.-H., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2018.09.002 · Cited by 310
Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant
Hu, L., McArthur, C., & Jaffe, R. B. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605626 · Cited by 296
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Moschetta, M., George, A., Kaye, S. B., & Banerjee, S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw142 · Cited by 292
Penson, R. T., Valencia, R. V., Cibula, D., Colombo, N., Leath, C. A., Bidziński, M., Kim, J.-W., Nam, J. H., Madry, R., Hernández, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02745 · Cited by 291
The Role of Tumor-Associated Macrophages in the Progression and Chemoresistance of Ovarian Cancer
Nowak, M., & Klink, M. (2020) · Cells · doi:10.3390/cells9051299 · Cited by 287
Reles, A., Wen, W., Schmider, A., Gee, C., Runnebaum, I. B., Kilian, U., Jones, L. A., El‐Naggar, A. K., Minguillon, C., Schönborn, I., et al. (2001) · PubMed · Cited by 282
Yang, Z., Schumaker, L. M., Egorin, M. J., Zuhowski, E. G., Guo, Z., & Cullen, K. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1037 · Cited by 267
Homologous recombination deficiency and ovarian cancer
Ledermann, J. A., Drew, Y., & Kristeleit, R. S. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.005 · Cited by 258
Yap, T. A., O’Carrigan, B., Penney, M. S., Lim, J. S., Brown, J. S., de Miguel Luken, M. J., Tunariu, N., Perez-Lopez, R., Rodrigues, D. N., Riisnaes, R., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02404 · Cited by 251
Blocking c-Met–mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors
Du, Y., Yamaguchi, H., Wei, Y., Hsu, J. L., Wang, H.-L., Hsu, Y.-H., Lin, W.-C., Yu, W.-H., Leonard, P. G., Lee, G. R., et al. (2016) · Nature Medicine · doi:10.1038/nm.4032 · Cited by 243
Frizzled-7 Identifies Platinum-Tolerant Ovarian Cancer Cells Susceptible to Ferroptosis
Wang, Y., Zhao, G., Condello, S., Huang, H., Cardenas, H., Tanner, E. J., Wei, J., Ji, Y., Li, J., Tan, Y., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1488 · Cited by 243
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Lister, A., Nedjadi, T., Kitteringham, N. R., Campbell, F., Costello, E., Lloyd, B., Copple, I. M., Williams, S., Owen, A., Neoptolemos, J. P., et al. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-37 · Cited by 242
Deng, J., Bai, X., Feng, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2019) · BMC Cancer · doi:10.1186/s12885-019-5824-9 · Cited by 242
Self-citationNaumann, R. W., Coleman, R. L., Burger, R. A., Sausville, E. A., Kutarska, E., Ghamande, S. A., Gabrail, N. Y., DePasquale, S. E., Nowara, E., Gilbert, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.7685 · Cited by 238
ARID1A-mutated ovarian cancers depend on HDAC6 activity
Bitler, B. G., Wu, S., Park, P. H., Hai, Y., Aird, K. M., Wang, Y., Zhai, Y., Kossenkov, A. V., Vara-Ailor, A., Rauscher III, F. J., et al. (2017) · Nature Cell Biology · doi:10.1038/ncb3582 · Cited by 232
Sun, C., Fang, Y., Yin, J., Chen, J., Ju, Z., Zhang, D., Chen, X., Vellano, C. P., Jeong, K. J., Ng, P. K.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5148 · Cited by 231
Moore, K. N., Martin, L. P., O’Malley, D. M., Matulonis, U. A., Konner, J. A., Perez, R. P., Bauer, T. M., Ruiz-Soto, R., & Birrer, M. J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9538 · Cited by 226
Synthetic lethality between CCNE1 amplification and loss of BRCA1
Etemadmoghadam, D., Weir, B. A., Au-Yeung, G., Alsop, K., Mitchell, G., George, J., Australian Ovarian Cancer Study Group, Davis, S., D’Andrea, A. D., Simpson, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1314302110 · Cited by 225
Konstantinopoulos, P. A., Cheng, S.-C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30180-7 · Cited by 225
Acquired chemotherapy resistance in ovarian cancer
Christie, E. L., & Bowtell, D. D. L. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx446 · Cited by 220
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells
He, Y. J., Meghani, K., Caron, M.-C., Yang, C., Ronato, D. A., Bian, J., Sharma, A., Moore, J., Niraj, J., Detappe, A., et al. (2018) · Nature · doi:10.1038/s41586-018-0670-5 · Cited by 219
Lee, J.-M., Nair, J., Zimmer, A., Lipkowitz, S., Annunziata, C. M., Merino, M. J., Swisher, E. M., Harrell, M. I., Trepel, J. B., Lee, M.-J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30009-3 · Cited by 209
Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma
Shen, G. H., Ghazizadeh, M., Kawanami, O., Shimizu, H., Jin, E., Araki, T., & Sugisaki, Y. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1228 · Cited by 201
Nakayama, N., Nakayama, K., Shamima, Y., Ishikawa, M., Katagiri, A., Iida, K., & Miyazaki, K. (2010) · Cancer · doi:10.1002/cncr.24987 · Cited by 201
Cancer Stem Cells and Chemosensitivity
Maugeri-Saccà, M., Vigneri, P., & De Maria, R. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2538 · Cited by 201
Phase II clinical trial of metformin as a cancer stem cell-targeting agent in ovarian cancer
Brown, J. R., Chan, D. K., Shank, J. J., Griffith, K. A., Fan, H., Szulawski, R., Yang, K., Reynolds, R. K., Johnston, C., McLean, K., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133247 · Cited by 198
Ai, Z., Lu, Y., Qiu, S., & Fan, Z. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.01.009 · Cited by 195
Wan, C., Keany, M. P., Dong, H., Al-Alem, L. F., Pandya, U. M., Lazo, S., Boehnke, K., Lynch, K. N., Xu, R., Zarrella, D. T., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-1674 · Cited by 193
Self-citationHu, Y.-L., Jahangiri, A., DeLay, M., & Aghi, M. K. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-1076 · Cited by 188
He, J., Yu, J.-J., Xu, Q., Wang, L., Zheng, J. Z., Liu, L.-Z., & Jiang, B.-H. (2015) · Autophagy · doi:10.1080/15548627.2015.1009781 · Cited by 179
Linking metabolic reprogramming to therapy resistance in cancer
Morandi, A., & Indraccolo, S. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.12.004 · Cited by 177
The impact of T‐cell immunity on ovarian cancer outcomes
Nelson, B. H. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00614.x · Cited by 172
Chemoresistance in human ovarian cancer: the role of apoptotic regulators
Fraser, M., Leung, B., Jahani-Asl, A., Yan, X., Thompson, W. E., & Tsang, B. K. (2003) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-1-66 · Cited by 170
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer
Lamichhane, P., Karyampudi, L., Shreeder, B., Krempski, J., Bahr, D., Daum, J., Kalli, K. R., Goode, E. L., Block, M. S., Cannon, M. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0740 · Cited by 170
The cancer stem-cell signaling network and resistance to therapy
Carnero, A., Garcia‐Mayea, Y., Mir, C., Lorente, J., Rubio, I. T., & LLeonart, M. E. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.07.001 · Cited by 159
Heparanase Enhances Tumor Growth and Chemoresistance by Promoting Autophagy
Shteingauz, A., Boyango, I., Naroditsky, I., Hammond, E., Gruber, M., Doweck, I., Ilan, N., & Vlodavsky, I. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0037 · Cited by 156
Karakashev, S. V., Fukumoto, T., Zhao, B., Lin, J., Wu, S., Fatkhutdinov, N., Park, P. H., Semenova, G., Jean, S., Cadungog, M. G., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2019.12.015 · Cited by 154
Au‐Yeung, G., Lang, F., Azar, W. J., Mitchell, T. J., Jarman, K. E., Lackovic, K., Aziz, D., Cullinane, C. M., Pearson, R. B., Mileshkin, L., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0620 · Cited by 150
The Pentose Phosphate Pathway and Its Involvement in Cisplatin Resistance
Giacomini, I., Ragazzi, E., Pasut, G., & Montopoli, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030937 · Cited by 150
Chemoresistance in ovarian cancer: exploiting cancer stem cell metabolism
Li, S., Ma, J., & Wong, A. S. T. (2018) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2018.29.e32 · Cited by 149
Ovarian cancer stem cells and targeted therapy
Keyvani, V., Farshchian, M., Esmaeili, S., Yari, H., Moghbeli, M., Nezhad, S. R. K., & Abbaszadegan, M. R. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0588-z · Cited by 149
p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma
Lavarino, C. E., Pilotti, S., Oggionni, M., Gatti, L., Perego, P., Bresciani, G., Pierotti, M. A., Scambia, G., Ferrandina, G., Fagotti, A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3936 · Cited by 147
Angiogenesis in the corpus luteum
Fraser, H. M., & Wulff, C. (2003) · Reproductive Biology and Endocrinology · doi:10.1186/1477-7827-1-88 · Cited by 147
Górski, J., Ueland, F. R., & Kolesar, J. (2020) · Diagnostics · doi:10.3390/diagnostics10050279 · Cited by 144
Iyer, S., Zhang, S., Yucel, S., Horn, H., Smith, S. G., Reinhardt, F., Hoefsmit, E., Assatova, B., Casado, J., Meinsohn, M.-C., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0818 · Cited by 136
Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance
Butler, E. B., Zhao, Y., Muñoz‐Pinedo, C., Lu, J., & Tan, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3009 · Cited by 135
Zhang, Y., Cheng, Y., Ren, X., Zhang, L., Yap, K. L., Wu, H., Patel, R., Liu, D., Qin, Z.-H., Shih, I., et al. (2011) · Oncogene · doi:10.1038/onc.2011.290 · Cited by 133
Yu, H., Su, J., Xu, Y., Kang, J., Li, H., Zhang, L., Yi, H., Xiang, X., Liu, F., & Sun, L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.01.019 · Cited by 130
Ovarian cancer: beyond resistance
Holmes, D. I. R. (2015) · Nature · doi:10.1038/527s217a · Cited by 128
Muñoz-Galván, S., Felipe‐Abrio, B., Verdugo‐Sivianes, E. M., Pérez, M., Jiménez-García, M. P., Suárez-Martínez, E., Estévez-García, P., & Carnero, A. (2020) · Molecular Cancer · doi:10.1186/s12943-020-1130-z · Cited by 122
Gupta, S., Nag, S. M., Aggarwal, S., Rauthan, A., & Warrier, N. E. (2019) · Journal of Ovarian Research · doi:10.1186/s13048-019-0579-0 · Cited by 116
Gralewska, P., Gajek, A., Marczak, A., & Rogalska, A. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00874-6 · Cited by 109
Stress management by autophagy: Implications for chemoresistance
Huang, Z., Zhou, L., Chen, Z., Nice, E. C., & Huang, C. (2016) · International Journal of Cancer · doi:10.1002/ijc.29990 · Cited by 106
Grisham, R. N., Sylvester, B. E., Won, H. H., McDermott, G. C., DeLair, D. F., Ramirez, R. J., Yao, Z., Shen, R., Dao, F., Bogomolniy, F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.4726 · Cited by 104
Chen, C., Cheng, W., Lee, C., Chen, T.-M., Kung, C.-C. S., Hsieh, F.-J., & Hsieh, C. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1999.5418 · Cited by 101
Ovarian Cancer: Diagnostic, Biological and Prognostic Aspects
Davidson, B., & Trope, C. G. (2014) · Women s Health · doi:10.2217/whe.14.37 · Cited by 98
Phase I Study of Folate Conjugate EC145 (Vintafolide) in Patients With Refractory Solid Tumors
LoRusso, P. M., Edelman, M. J., Bever, S. L., Forman, K., Pilat, M., Quinn, M. F., Li, J., Heath, E. I., Malburg, L., Klein, P. J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4946 · Cited by 98
Coleman, R. L., Duska, L., Ramirez, P. T., Heymach, J. V., Kamat, A. A., Modesitt, S. C., Schmeler, K. M., Iyer, R. B., Garcia, M. E., Miller, D. L., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70244-3 · Cited by 96
STAT3 signaling in ovarian cancer: a potential therapeutic target
Liang, R., Chen, X., Chen, L., Wan, F., Chen, K.-H., Sun, Y., & Zhu, X. (2019) · Journal of Cancer · doi:10.7150/jca.35011 · Cited by 94
DNA damage repair in ovarian cancer: unlocking the heterogeneity
Gee, M. E., Faraahi, Z., McCormick, A., & Edmondson, R. J. (2018) · Journal of Ovarian Research · doi:10.1186/s13048-018-0424-x · Cited by 93
Garsed, D. W., Alsop, K., Fereday, S., Emmanuel, C., Kennedy, C. J., Etemadmoghadam, D., Gao, B., Gebski, V., Garès, V., Christie, E. L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1621 · Cited by 91
Increased oxidative stress mediates the antitumor effect of PARP inhibition in ovarian cancer
Hou, D., Liu, Z., Xu, X., Liu, Q., Zhang, X., Kong, B., Wei, J., Gong, Y., & Shao, C. (2018) · Redox Biology · doi:10.1016/j.redox.2018.03.016 · Cited by 90
Tumor‐associated macrophage‐targeted therapeutics in ovarian cancer
An, Y., & Yang, Q. (2020) · International Journal of Cancer · doi:10.1002/ijc.33408 · Cited by 90
Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian Cancer
Baekelandt, M. M. O., Kristensen, G. B., Nesland, J. M., Trope, C. G., & Holm, R. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2061 · Cited by 88
Ovarian cancer predisposition beyond BRCA1 and BRCA2 genes
Pietragalla, A., Arcieri, M., Marchetti, C., Scambia, G., & Fagotti, A. (2020) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2020-001556 · Cited by 85
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 82
Therapeutic Inducers of Apoptosis in Ovarian Cancer
Binju, M., Amaya-Padilla, M. A., Wan, G., Gunosewoyo, H., Rahmanto, Y. S., & Yu, Y. (2019) · Cancers · doi:10.3390/cancers11111786 · Cited by 82
Immunotherapy for platinum-resistant ovarian cancer
Bogani, G., Lopez, S., Mantiero, M., Ducceschi, M., Bosio, S., Ruisi, S., Sarpietro, G., Guerrisi, R., Brusadelli, C., Dell'acqua, A., et al. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2020.05.681 · Cited by 82
Ashrafizadeh, M., Zarrabi, A., Orouei, S., Hushmandi, K., Hakimi, A., Zabolian, A., Daneshi, S., Samarghandian, S., Baradaran, B., & Najafi, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173660 · Cited by 76
Baekelandt, M. M. O., Holm, R., Nesland, J. M., Trope, C. G., & Kristensen, G. B. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.22.3775 · Cited by 74
Inhibition of cancer stem cell like cells by a synthetic retinoid
Chen, J., Cao, X., An, Q., Zhang, Y., Li, K., Yao, W., Shi, F., Pan, Y., Jia, Q., Zhou, W., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03877-7 · Cited by 72
Prexasertib, a checkpoint kinase inhibitor: from preclinical data to clinical development
Angius, G., Tomao, S., Stati, V., Vici, P., Bianco, V., & Tomao, F. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03950-y · Cited by 72
Zervantonakis, I. K., Iavarone, C., Chen, H., Selfors, L. M., Palakurthi, S. S., Liu, J. F., Drapkin, R., Matulonis, U. A., Leverson, J. D., Sampath, D., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00263-7 · Cited by 67
A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer
Choi, H. J., Heo, J. H., Park, J. Y., Jeong, J. Y., Cho, H. J., Park, K. S., Kim, S. H., Moon, Y. W., Kim, J. S., & An, H. J. (2019) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.01.012 · Cited by 66
A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer
Nwani, N. G., Condello, S., Wang, Y., Swetzig, W. M., Barber, E. L., Hurley, T. D., & Matei, D. E. (2019) · Cancers · doi:10.3390/cancers11040502 · Cited by 66
Baekelandt, M. M. O., Lehne, G., Tropé, C. G., Szántó, I., Pfeiffer, P., Gustavssson, B., & Kristensen, G. B. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.12.2983 · Cited by 64
Combination of KRAS gene silencing and PI3K inhibition for ovarian cancer treatment
Kim, M. J., Lee, S. J., Ryu, J. H., Kim, S. H., Kwon, I. C., & Roberts, T. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.12.019 · Cited by 64
Cruz, I. N., Coley, H. M., Kramer, H., Madhuri, T. K., Safuwan, N. A. M., ANGELINO, A. R., & Yang, M. (2017) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20017 · Cited by 61
Marzi, L., Szabova, L., Gordon, M., Weaver Ohler, Z., Sharan, S. K., Beshiri, M. L., Etemadi, M., Murai, J., Kelly, K., & Pommier, Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0419 · Cited by 60
Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancer
Verschoor, M. L., & Singh, G. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-138 · Cited by 56
Overcoming platinum-acquired resistance in ovarian cancer patient-derived xenografts
Ricci, F., Brunelli, L., Affatato, R., Chilà, R., Verza, M., Indraccolo, S., Falcetta, F., Fratelli, M., Fruscio, R., Pastorelli, R., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919839543 · Cited by 54
Role of the transcription factor Ets-1 in cisplatin resistance
Wilson, A., Yamamoto, H., & Singh, G. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.823.3.7 · Cited by 52
Reversion Mutations with Clinical Use of PARP Inhibitors: Many Genes, Many Versions
Domchek, S. M. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0734 · Cited by 51
NFATC4 promotes quiescence and chemotherapy resistance in ovarian cancer
Cole, A. J., Iyengar, M., Panesso-Gómez, S., O’Hayer, P., Chan, D., Delgoffe, G. M., Aird, K. M., Yoon, E., Bai, S., & Buckanovich, R. J. (2020) · JCI Insight · doi:10.1172/jci.insight.131486 · Cited by 50
Yan, S., Xuan, J., Brajanovski, N., Tancock, M. R. C., Madhamshettiwar, P. B., Simpson, K. J., Ellis, S. L., Kang, J., Cullinane, C. M., Sheppard, K. E., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01158-z · Cited by 48
Kim, T. H., Suh, D. H., Kim, M., & Song, Y. S. (2014) · BioMed Research International · doi:10.1155/2014/132702 · Cited by 47
Metformin and ovarian cancer: the evidence
Urpilainen, E., Puistola, U., Boussios, S., & Karihtala, P. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-1060 · Cited by 47
Chui, M. H., Boroujeni, A. M., Mandelker, D. L., Ladanyi, M., & Soslow, R. A. (2020) · Modern Pathology · doi:10.1038/s41379-020-00648-y · Cited by 42
Inhibition of autophagy initiation potentiates chemosensitivity in mesothelioma
Follo, C., Cheng, Y., Richards, W. G., Bueno, R., & Broaddus, V. C. (2017) · Molecular Carcinogenesis · doi:10.1002/mc.22757 · Cited by 35
The Role of CDKs and CDKIs in Murine Development
Campbell, G. J., Hands, E. L., & de Pette, M. V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155343 · Cited by 35
da Costa, A. A. B. A., do Canto, L. M., Larsen, S. J., Ribeiro, A. R. G., Stecca, C., Petersen, A. H., Aagaard, M. M., Brot, L. D., Baumbach, J., Baiocchi, G., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-5622-4 · Cited by 33
Shi, M., Whorton, A. E., Sekulovski, N., Paquet, M., MacLean, J. A., Song, Y., Dyke, T. V., & Hayashi, K. (2020) · Biology of Reproduction · doi:10.1093/biolre/ioaa008 · Cited by 27
Programmed cell death ligand‐1: A dynamic immune checkpoint in cancer therapy
Kalim, M., Khan, M. S. I., & Zhan, J. (2020) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13677 · Cited by 27
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion
van der Wijst, M. G. P., Huisman, C., Mposhi, A., Roelfes, G., & Rots, M. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.003 · Cited by 25
The tubal epigenome – An emerging target for ovarian cancer
Reavis, H. D., & Drapkin, R. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107524 · Cited by 20
Spectrum ofBRAFMutations and Gene Rearrangements in Ovarian Serous Carcinoma
Chui, M. H., Chang, J. C., Zhang, Y., Zehir, A., Schram, A. M., Konner, J. A., Drilon, A. E. D. C., Paula, A. D. C., Weigelt, B., & Grisham, R. N. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00055 · Cited by 19
Emerging roles of lamins and DNA damage repair mechanisms in ovarian cancer
Sengupta, D., Mukhopadhyay, A., & Sengupta, K. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200713 · Cited by 14
Metadata
- Authors
- Yang, L., Xie, H.-J., Li, Y.-Y., Wang, X., Liu, X.-X., & Mai, J.
- Venue
- Oncology Reports
- Publisher
- Spandidos Publications
- Published
- 2022-02-25
- Volume
- 47
- Issue
- 4
- ISSN
- 1021-335X (ISSN-L)
- 1791-2431
- OpenAlex
- W4214731166
- Cited by
- 304
- References
- 136
- FWCI
- 40.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.